Clinical utility of a novel urine-based gene fusion TTTY15-USP9Y in predicting prostate biopsy outcome..     ///    "In conclusion, our study explored the potential utility of measuring the TTTY15-USP9Y score in post-digital rectal examination urine samples to predict biopsy outcome and provided the basis for the utility of this novel gene fusion in multicenter and large cohort studies.. "    ///    "The TTTY15-USP9Y score was calculated as 2(Ct(PSA)-Ct(TTTY15-USP9Y))?? 1,000. "    ///    "Univariable and multivariable logistic analyses indicated that TTTY15-USP9Y score, PSA level, age, and prostate volume were independent predictors of PCa. "    ///    "Adding the TTTY15-USP9Y score in the clinical base model (PSA level, age, and prostate volume) could bring a higher net benefit and reduce more unnecessary biopsies in the defined range of interest (10%-40% threshold probability). "    ///    We retrospectively examined the expression of TTTY15-USP9Y in 226 qualified urine sediment samples.     ///    The combination of PSA level and the TTTY15-USP9Y score significantly improved the diagnostic performance of PSA level (P = 0.001).     ///    Our previous study has demonstrated the high prevalence of TTTY15-USP9Y in prostate cancer samples from a Chinese population.     ///    The TTTY15-USP9Y score was statistically significantly higher in men with positive biopsy outcome than in men with negative biopsy outcome (P<0.001).     ///    Our aim was to evaluate the clinical utility of TTTY15-USP9Y in predicting the prostate biopsy outcome.     ///    "The TTTY15-USP9Y score alone was superior to PSA level, percent free PSA, and PSA density (serum PSA/prostate volume) in the subgroup of clinical interest (PSA level: 4-10ng/ml, gray zone). "    ///    The area under the curve was 0.828 for the TTTY15-USP9Y score in the entire patient cohort.     ///    The TTTY15-USP9Y score?s cutoff of 90.28 provided the optimal balance between sensitivity (84.0%) and specificity (77.5%).     ///    Real-time quantitative polymerase chain reaction was performed to evaluate the expression of TTTY15-USP9Y and the prostate cancer-specific antigen (PSA) level. 